Nf1+/- monocytes/macrophages induce neointima formation via CCR2 activation

Human Molecular Genetics

Volumn 25, Issue 6, 2015, Pages 1129-1139

  Bessler, Waylan K ^a,b   Kim, Grace ^c   Hudson, Farlyn Z ^c   Mund, Julie A ^a,b   Mali, Raghuveer ^a,b   Menon, Keshav ^a,b   Kapur, Reuben ^a,b   Clapp, D Wade ^a,b   Ingram, David A ^a,b   Stansfield, Brian K ^c  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Department of Pediatrics and Neonatal Perinatal Medicine ^*  (United States)

^c MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR2 ANTAGONIST; INCB 3284; MITOGEN ACTIVATED PROTEIN KINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUROFIBROMIN; PROTEIN KINASE B; CCR2 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ARTERY WALL; ARTICLE; BONE MARROW DERIVED MACROPHAGE; CAROTID ARTERY; CELL ISOLATION; CELL PROLIFERATION; CONTROLLED STUDY; GENE DELETION; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MONOCYTE; MOUSE; NEOINTIMA; NEUROFIBROMATOSIS TYPE 1; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; GENETICS; KNOCKOUT MOUSE; MALE; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; SMOOTH MUSCLE CELL; TUMOR SUPPRESSOR GENE;

ANIMALS; CAROTID ARTERIES; CHEMOKINE CCL2; GENES, NEUROFIBROMATOSIS 1; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MONOCYTES; MYOCYTES, SMOOTH MUSCLE; NEOINTIMA; NEUROFIBROMATOSIS 1; NEUROFIBROMIN 1; RECEPTORS, CCR2; SIGNAL TRANSDUCTION;

EID: 84960124044     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddv635     Document Type: Article

References (65)

1. Staser, K., Park, S.J., Rhodes, S.D., Zeng, Y., He, Y.Z., Shew, M. A., Gehlhausen, J.R., Cerabona, D., Menon, K., Chen, S. et al. (2013) Normal hematopoiesis and neurofibromin-deficient myeloproliferative disease require Erk. J. Clin. Invest., 123, 329-334.
2. Friedman, J.M., Arbiser, J., Epstein, J.A., Gutmann, D.H., Huot, S.J., Lin, A.E., McManus, B. and Korf, B.R. (2002) Cardiovascular disease in neurofibromatosis 1: report of the NF1 cardiovascular task force. Genet. Med., 4, 105-111.
3. Oderich, G.S., Sullivan, T.M., Bower, T.C., Gloviczki, P., Miller, D.V., Babovic-Vuksanovic, D., Macedo, T.A. and Stanson, A. (2007) Vascular abnormalities in patients with neurofibromatosis syndrome type I: clinical spectrum, management, and results. J. Vasc. Surg., 46, 475-484.
4. Rasmussen, S.A., Yang, Q. and Friedman, J.M. (2001) Mortality in neurofibromatosis 1: an analysis using U.S. death certificates. Am. J. Hum. Genet., 68, 1110-1118.
5. Lin, A.E., Birch, P.H., Korf, B.R., Tenconi, R., Niimura, M., Poyhonen, M., Armfield Uhas, K., Sigorini, M., Virdis, R., Romano, C. et al. (2000) Cardiovascular malformations and other cardiovascular abnormalities in neurofibromatosis 1. Am. J. Med. Genet., 95, 108-117.
6. D'Arco, F., D'Amico, A., Caranci, F., Di Paolo, N., Melis, D. and Brunetti, A. (2014) Cerebrovascular stenosis in neurofibromatosis type 1 and utility of magnetic resonance angiography: our experience and literature review. Radiol. Med., 119, 415-421.
7. Rea, D., Brandsema, J.F., Armstrong, D., Parkin, P.C., deVeber, G., MacGregor, D., Logan, W.J. and Askalan, R. (2009) Cerebral arteriopathy in children with neurofibromatosis type 1. Pediatrics, 124, e476-e483.
8. Salyer, W.R. and Salyer, D.C. (1974) The vascular lesions of neurofibromatosis. Angiology, 25, 510-519.
9. Kanter, R.J., Graham, M., Fairbrother, D. and Smith, S.V. (2006) Sudden cardiac death in young children with neurofibromatosis type 1. J. Pediatr., 149, 718-720.
10. Hamilton, S.J. and Friedman, J.M. (2000) Insights into the pathogenesis of neurofibromatosis 1 vasculopathy. Clin. Genet., 58, 341-344.
11. Lie, J.T. (1998) Vasculopathies of neurofibromatosis type 1 (von Recklinghausen Disease). Cardiovasc. Pathol., 7, 97-108.
12. +/-mice have increased neointima formation via hyperactivation of a Gleevec sensitive molecular pathway. Hum. Mol. Genet., 17, 2336-2344.
13. Lasater, E.A., Li, F., Bessler, W.K., Estes, M.L., Vemula, S., Hingtgen, C.M., Dinauer, M.C., Kapur, R., Conway, S.J. and Ingram, D.A. Jr. (2010) Genetic and cellular evidence of vascular inflammation in neurofibromin-deficient mice and humans. J. Clin. Invest., 120, 859-870.
14. Li, F., Munchhof, A.M., White, H.A., Mead, L.E., Krier, T.R., Fenoglio, A., Chen, S., Wu, X., Cai, S., Yang, F.C. et al. (2006) Neurofibromin is a novel regulator of RAS-induced signals in primary vascular smooth muscle cells. Hum. Mol. Genet., 15, 1921-1930.
15. Stansfield, B.K., Bessler, W.K., Mali, R., Mund, J.A., Downing, B., Li, F., Sarchet, K.N., DiStasi, M.R., Conway, S.J., Kapur, R. et al. (2013) Heterozygous inactivation of the Nf1 gene in myeloid cells enhances neointima formation via a rosuvastatinsensitive cellular pathway. Hum. Mol. Genet., 22, 977-988.
16. Stansfield, B.K. and Ingram, D.A. (2015) Clinical significance of monocyte heterogeneity. Clin. Transl. Med., 4, 5.
17. Hilgendorf, I., Gerhardt, L.M., Tan, T.C., Winter, C., Holderried, T.A., Chousterman, B.G., Iwamoto, Y., Liao, R., Zirlik, A., Scherer-Crosbie, M. et al. (2014) Ly-6C high monocytes depend on Nr4a1 to balance both inflammatory and reparative phases in the infarcted myocardium. Circ. Res., 114, 1611-1622.
18. Robbins, C.S., Chudnovskiy, A., Rauch, P.J., Figueiredo, J.L., Iwamoto, Y., Gorbatov, R., Etzrodt, M., Weber, G.F., Ueno, T., van Rooijen, N. et al. (2012) Extramedullary hematopoiesis generates Ly-6C (high) monocytes that infiltrate atherosclerotic lesions. Circulation, 125, 364-374.
19. Giunti, S., Pinach, S., Arnaldi, L., Viberti, G., Perin, P.C., Camussi, G. and Gruden, G. (2006) The MCP-1/CCR2 system has direct proinflammatory effects in human mesangial cells. Kidney Int., 69, 856-863.
20. Tieu, B.C., Lee, C., Sun, H., Lejeune, W., Recinos, A. 3rd, Ju, X., Spratt, H., Guo, D.C., Milewicz, D., Tilton, R.G. et al. (2009) An adventitial IL-6/MCP1 amplification loop accelerates macrophage-mediated vascular inflammation leading to aortic dissection in mice. J. Clin. Invest., 119, 3637-3651.
21. Sakai, N., Wada, T., Furuichi, K., Shimizu, K., Kokubo, S., Hara, A., Yamahana, J., Okumura, T., Matsushima, K., Yokoyama, H. et al. (2006) MCP-1/CCR2-dependent loop for fibrogenesis in human peripheral CD14-positive monocytes. J. Leukoc. Biol., 79, 555-563.
22. Lin, Y.M., Hsu, C.J., Liao, Y.Y., Chou, M.C. and Tang, C.H. (2012) The CCL2/CCR2 axis enhances vascular cell adhesion molecule-1 expression in human synovial fibroblasts. PLoS ONE, 7, e49999.
23. Kalderen, C., Forsgren, M., Karlstrom, U., Stefansson, K., Svensson, R., Berglund, M.M., Palm, G., Selander, M., Sundbom, M., Nilsson, J. et al. (2012) A truncated analogue of CCL2 mediates anti-fibrotic effects on murine fibroblasts independently of CCR2. Biochem. Pharmacol., 83, 644-652.
24. Si, Y., Tsou, C.L., Croft, K. and Charo, I.F. (2010) CCR2 mediates hematopoietic stem and progenitor cell trafficking to sites of inflammation in mice. J. Clin. Invest., 120, 1192-1203.
25. Tsou, C.L., Peters, W., Si, Y., Slaymaker, S., Aslanian, A.M., Weisberg, S.P., Mack, M. and Charo, I.F. (2007) Critical roles for CCR2 and MCP-3 in monocyte mobilization from bone marrowand recruitment to inflammatory sites. J. Clin. Invest., 117, 902-909.
26. Hartl, D., Krauss-Etschmann, S., Koller, B., Hordijk, P.L., Kuijpers, T.W., Hoffmann, F., Hector, A., Eber, E., Marcos, V., Bittmann, I. et al. (2008) Infiltrated neutrophils acquire novel chemokine receptor expression and chemokine responsiveness in chronic inflammatory lung diseases. J. Immunol., 181, 8053-8067.
27. Stansfield, B.K., Bessler, W.K., Mali, R., Mund, J.A., Downing, B. D., Kapur, R. and Ingram, D.A. Jr. (2014) Ras-mek-erk signaling regulates nf1 heterozygous neointima formation. Am. J. Pathol., 184, 79-85.
28. Maddaluno, M., Grassia, G., Di Lauro, M.V., Parisi, A., Maione, F., Cicala, C., De Filippis, D., Iuvone, T., Guglielmotti, A., Maffia, P. et al. (2012) Bindarit inhibits human coronary artery smooth muscle cell proliferation, migration and phenotypic switching. PLoS ONE, 7, e47464.
29. Porreca, E., Di Febbo, C., Reale, M., Castellani, M.L., Baccante, G., Barbacane, R., Conti, P., Cuccurullo, F. and Poggi, A. (1997) Monocyte chemotactic protein 1 (MCP-1) is a mitogen for cultured rat vascular smooth muscle cells. J. Vasc. Res., 34, 58-65.
30. Selzman, C.H., Miller, S.A., Zimmerman, M.A., Gamboni-Robertson, F., Harken, A.H. and Banerjee, A. (2002) Monocyte chemotactic protein-1 directly induces human vascular smooth muscle proliferation. Am J Physiol. Heart Circ. Physiol., 283, H1455-H1461.
31. Viedt, C., Vogel, J., Athanasiou, T., Shen, W., Orth, S.R., Kubler, W. and Kreuzer, J. (2002) Monocyte chemoattractant protein-1 induces proliferation and interleukin-6 production in human smooth muscle cells by differential activation of nuclear factor-kappaB and activator protein-1. Arterioscler. Thromb. Vasc. Biol., 22, 914-920.
32. Kim, M.S., Magno, C.L., Day, C.J. and Morrison, N.A. (2006) Induction of chemokines and chemokine receptors CCR2b and CCR4 in authentic human osteoclasts differentiated with RANKL and osteoclast like cells differentiated by MCP-1 and RANTES. J. Cell. Biochem., 97, 512-518.
33. Schecter, A.D., Berman, A.B., Yi, L., Ma, H., Daly, C.M., Soejima, K., Rollins, B.J., Charo, I.F. and Taubman, M.B. (2004) MCP-1-dependent signaling in CCR2(-/-) aortic smooth muscle cells. J. Leukoc. Biol., 75, 1079-1085.
34. Xue, C.B., Feng, H., Cao, G., Huang, T., Glenn, J., Anand, R., Meloni, D., Zhang, K., Kong, L., Wang, A. et al. (2011) Discovery of INCB3284, a potent, selective, and orally bioavailable hCCR2 antagonist. ACS Med. Chem. Lett., 2, 450-454.
35. Libby, P., Nahrendorf, M. and Swirski, F.K. (2013) Monocyte heterogeneity in cardiovascular disease. Semin. Immunopathol., 35, 553-562.
36. Serbina, N.V. and Pamer, E.G. (2006) Monocyte emigration from bone marrow during bacterial infection requires signals mediated by chemokine receptor CCR2. Nat. Immunol., 7, 311-317.
37. Ishibashi, M., Egashira, K., Zhao, Q., Hiasa, K., Ohtani, K., Ihara, Y., Charo, I.F., Kura, S., Tsuzuki, T., Takeshita, A. et al. (2004) Bone marrow-derived monocyte chemoattractant protein-1 receptor CCR2 is critical in angiotensin II-induced acceleration of atherosclerosis and aneurysm formation in hypercholesterolemic mice. Arterioscler. Thromb. Vasc. Biol., 24, e174-e178.
38. Liehn, E.A., Piccinini, A.M., Koenen, R.R., Soehnlein, O., Adage, T., Fatu, R., Curaj, A., Popescu, A., Zernecke, A., Kungl, A.J. et al. (2010) A new monocyte chemotactic protein-1/chemokine CC motif ligand-2 competitor limiting neointima formation and myocardial ischemia/reperfusion injury in mice. J. Am. College Cardiol., 56, 1847-1857.
39. Schober, A., Zernecke, A., Liehn, E.A., von Hundelshausen, P., Knarren, S., Kuziel, W.A. and Weber, C. (2004) Crucial role of the CCL2/CCR2 axis in neointimal hyperplasia after arterial injury in hyperlipidemic mice involves early monocyte recruitment and CCL2 presentation on platelets. Circ. Res., 95, 1125-1133.
40. Kuhel, D.G., Zhu, B., Witte, D.P. and Hui, D.Y. (2002) Distinction in genetic determinants for injury-induced neointimal hyperplasia and diet-induced atherosclerosis in inbred mice. Arterioscler. Thromb. Vasc. Biol., 22, 955-960.
41. Gong, X., Gong, W., Kuhns, D.B., Ben-Baruch, A., Howard, O.M. andWang, J.M. (1997) Monocyte chemotactic protein-2 (MCP-2) uses CCR1 and CCR2B as its functional receptors. J. Biol. Chem., 272, 11682-11685.
42. Maddaluno, M., Di Lauro, M., Di Pascale, A., Santamaria, R., Guglielmotti, A., Grassia, G. and Ialenti, A. (2011) Monocyte chemotactic protein-3 induces human coronary smooth muscle cell proliferation. Atherosclerosis, 217, 113-119.
43. Li, X. and Tai, H.H. (2013) Activation of thromboxane A2 receptor (TP) increases the expression of monocyte chemoattractant protein-1 (MCP-1)/chemokine (C-C motif ) ligand 2 (CCL2) and recruits macrophages to promote invasion of lung cancer cells. PLoS ONE, 8, e54073.
44. Lim, J.H., Um, H.J., Park, J.W., Lee, I.K. and Kwon, T.K. (2009) Interleukin-1beta promotes the expression of monocyte chemoattractant protein-1 in human aorta smooth muscle cells via multiple signaling pathways. Exp. Mol. Med., 41, 757-764.
45. Shimizu, H., Bolati, D., Higashiyama, Y., Nishijima, F., Shimizu, K. and Niwa, T. (2012) Indoxyl sulfate upregulates renal expression of MCP-1 via production of ROS and activation of NF-kappaB, p53, ERK, and JNK in proximal tubular cells. Life Sci., 90, 525-530.
46. Shang, F., Wang, J., Liu, X., Li, J., Zheng, Q., Xue, Y. and Zhao, L. (2012) Involvement of reactive oxygen species and JNK in increased expression of MCP-1 and infiltration of inflammatory cells in pressure-overloaded rat hearts. Mol. Med. Rep., 5, 1491-1496.
47. Jimenez-Sainz, M.C., Fast, B., Mayor, F. Jr and Aragay, A.M. (2003) Signaling pathways for monocyte chemoattractant protein 1-mediated extracellular signal-regulated kinase activation. Mol. Pharmacol., 64, 773-782.
48. Patial, S., Saini, Y., Parvataneni, S., Appledorn, D.M., Dorn, G. W. 2nd, Lapres, J.J., Amalfitano, A., Senagore, P. and Parameswaran, N. (2011) Myeloid-specific GPCR kinase-2 negatively regulates NF-kappaB1p105-ERK pathway and limits endotoxemic shock in mice. J. Cell. Physiol., 226, 627-637.
49. Yang, C.Q., Li, W., Li, S.Q., Li, J., Li, Y.W., Kong, S.X., Liu, R.M., Wang, S.M. and Lv, W.M. (2014) MCP-1 stimulates MMP-9 expression via ERK 1/2 and p38 MAPK signaling pathways in human aortic smooth muscle cells. Cell. Physiol. Biochem., 34, 266-276.
50. Arefieva, T.I., Krasnikova, T.L., Potekhina, A.V., Ruleva, N.U., Nikitin, P.I., Ksenevich, T.I., Gorshkov, B.G., Sidorova, M.V., Bespalova Zh, D., Kukhtina, N.B. et al. (2011) Synthetic peptide fragment (65-76) of monocyte chemotactic protein-1 (MCP-1) inhibits MCP-1 binding to heparin and possesses anti-inflammatory activity in stable angina patients after coronary stenting. Inflamm. Res., 60, 955-964.
51. Egashira, K., Nakano, K., Ohtani, K., Funakoshi, K., Zhao, G., Ihara, Y., Koga, J., Kimura, S., Tominaga, R. and Sunagawa, K. (2007) Local delivery of anti-monocyte chemoattractant protein-1 by gene-eluting stents attenuates in-stent stenosis in rabbits and monkeys. Arterioscler. Thromb. Vasc. Biol., 27, 2563-2568.
52. Nakano, K., Egashira, K., Ohtani, K., Zhao, G., Funakoshi, K., Ihara, Y. and Sunagawa, K. (2007) Catheter-based adenovirus-mediated anti-monocyte chemoattractant gene therapy attenuates in-stent neointima formation in cynomolgusmonkeys. Atherosclerosis, 194, 309-316.
53. Ohtani, K., Usui, M., Nakano, K., Kohjimoto, Y., Kitajima, S., Hirouchi, Y., Li, X.H., Kitamoto, S., Takeshita, A. and Egashira, K. (2004) Antimonocyte chemoattractant protein-1 gene therapy reduces experimental in-stent restenosis in hypercholesterolemic rabbits and monkeys. Gene Ther., 11, 1273-1282.
54. Zhao, Q. (2010) Dual targeting of CCR2 and CCR5: therapeutic potential for immunologic and cardiovascular diseases. J. Leukoc. Biol., 88, 41-55.
55. Ialenti, A., Grassia, G., Gordon, P., Maddaluno, M., Di Lauro, M. V., Baker, A.H., Guglielmotti, A., Colombo, A., Biondi, G., Kennedy, S. et al. (2011) Inhibition of in-stent stenosis by oral administration of bindarit in porcine coronary arteries. Arterioscler. Thromb. Vasc. Biol., 31, 2448-2454.
56. Grassia, G., Maddaluno, M., Guglielmotti, A., Mangano, G., Biondi, G., Maffia, P. and Ialenti, A. (2009) The anti-inflammatory agent bindarit inhibits neointima formation in both rats and hyperlipidaemic mice. Cardiovasc. Res., 84, 485-493.
57. Haringman, J.J., Gerlag, D.M., Smeets, T.J., Baeten, D., Van Den Bosch, F., Bresnihan, B., Breedveld, F.C., Dinant, H.J., Legay, F., Gram, H. et al. (2006) A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis. Arthritis Rheum., 54, 2387-2392.
58. Westerbacka, J., Corner, A., Kolak, M., Makkonen, J., Turpeinen, U., Hamsten, A., Fisher, R.M. and Yki-Jarvinen, H. (2008) Insulin regulation ofMCP-1 inhuman adipose tissue of obese and lean women. Am. J. Physiol. Endocrinol. Metab., 294, E841-E845.
59. Younce, C. and Kolattukudy, P. (2012) MCP-1 induced protein promotes adipogenesis via oxidative stress, endoplasmic reticulum stress and autophagy. Cell. Physiol. Biochem., 30, 307-320.
60. Lin, K.L., Sweeney, S., Kang, B.D., Ramsburg, E. and Gunn, M. D. (2011) CCR2-antagonist prophylaxis reduces pulmonary immune pathology and markedly improves survival during influenza infection. J. Immunol., 186, 508-515.
61. Mildner, A., Mack, M., Schmidt, H., Bruck, W., Djukic, M., Zabel, M.D., Hille, A., Priller, J. and Prinz, M. (2009) CCR2+Ly-6Chi monocytes are crucial for the effector phase of autoimmunity in the central nervous system. Brain, 132, 2487-2500.
62. Sullivan, T.J., Miao, Z., Zhao, B.N., Ertl, L.S., Wang, Y., Krasinski, A., Walters, M.J., Powers, J.P., Dairaghi, D.J., Baumgart, T. et al. (2013) Experimental evidence for the use of CCR2 antagonists in the treatment of type 2 diabetes. Metabolism: Clin. Exp., 62, 1623-1632.
63. Gritsman, K., Yuzugullu, H., Von, T., Yan, H., Clayton, L., Fritsch, C., Maira, S.M., Hollingworth, G., Choi, C., Khandan, T. et al. (2014) Hematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110alpha. J. Clin. Invest., 124, 1794-1809.
64. Zeng, Y., Broxmeyer, H.E., Staser, K., Chitteti, B.R., Park, S.J., Hahn, S., Cooper, S., Sun, Z., Jiang, L., Yang, X. et al. (2015) Pak2 regulates hematopoietic progenitor cell proliferation, survival and differentiation. Stem Cells, 33, 1630-1641.
65. Bollag, G., Clapp, D.W., Shih, S., Adler, F., Zhang, Y.Y., Thompson, P., Lange, B.J., Freedman, M.H., McCormick, F., Jacks, T. et al. (1996) Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. Nat. Genet., 12, 144-148.